VbP treatment is known to either activate NLRP1 (e.g. in keratinocytes) or CARD8 (e.g. in myeloid leukemia cell lines; Johnson et al, 2018; Zhong et al, 2018). Here, NLRP1 is linked to myeloid leukemia.